Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Domvanalimab (Primary) ; Zimberelimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Nivolumab; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR-221
  • Sponsors Arcus Biosciences; Taiho Pharmaceutical

    • Most Recent Events

    • 11 Jun 2024 Planned End Date changed from 1 Jan 2027 to 1 May 2026.
    • 11 Jun 2024 Planned primary completion date changed from 1 Sep 2026 to 1 May 2026.
    • 10 Jun 2024 According to an Arcus Biosciences media release, the company announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top